On August 15, the Investor Research Institute under the Investor Network released the "2023 China Fund Partner Annual List". With outstanding investment and management performance, PCG Capital Chairman Qian Mingfei was awarded the "2022-2023 Best Investor 」.

through questionnaire research, data verification and other processes, the investor research institute took several months to select qualified investment institutions/investors on the list, and witnessed the highlight moment of VC/PE together with the market.

Qian Mingfei has nearly 20 years of experience in equity investment and corporate management, focusing on the fields of life sciences, dual-carbon technology, and hard-core technology, leading investment in Kanghua Biology (300841), Sanyou Medical (688085), Zhuhai Guanyu (688772), Ruida (688800), Pris (301257), Yahong Medicine (688176), Mengke Pharmaceutical (688373), Torch Electronics (603678), GAC An, Wanxiang 123, Yuexin Semiconductor, Pilot Film and many other equity projects, and holding-type investment love pet biology, Presun Pharmaceuticals and other enterprises, to achieve excellent performance returns.

Adhering to the mission of "discovering the power of economic progress", we are committed to working with like-minded entrepreneurs to achieve extraordinary technological innovation. Under the leadership of Mr. Qian Mingfei, PCG Capital has been among the top ten in China's equity investment industry. It has laid out more than 300 leading enterprises in the three core tracks of life science, double carbon technology and hard technology, thus forming an industrial ecosystem with high links and resource coordination.

entering 2023, guiding funds and industrial funds will blossom everywhere. VC/PE is focusing on two major directions: one is to break through the "stuck neck" technology in hard technology industries such as chip semiconductors, biomedicine and high-end equipment; The other is AI, Internet of Things and other soft technology industries that drive the digitalization of the industry. Pacific Century Capital believes that disruptive technological innovation will bring greater imagination to the industry. Pacific Century will continue to work with LP, shareholders and entrepreneurial innovators to write a brilliant page in China's science and technology.